This response is numerically higher than previous clinical trial experience with anti-PD-L1 monotherapy regardless of prior platinum exposure for recurrent/metastatic disease.6 26 In addition, prolonged SD was seen in most CPI-naïve patients, with an overall clinical benefit rate (CR+PR+SD) of 61.1%. Here, CD274 is linked to metastatic neoplasm.